Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €15.36 EUR
Change Today +0.187 / 1.23%
Volume 100.0
As of 12:47 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (D4S) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/15 - €19.59
52 Week Low
01/9/15 - €11.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAIICHI SANKYO CO LTD (D4S)

Related News

No related news articles were found.

daiichi sankyo co ltd (D4S) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (D4S) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. The company’s generic pharmaceuticals include olmesartan, azelnidipine, and amlodipine antihypertensive agents; loxoprofen, an anti-inflammatory analgesic; levofloxacin, a synthetic antibacterial agent; esomeprazole for ulcer treatment; memantine and donepezil for treating alzheimer’s disease; pravastatin and atorvastatin antihyperlipidemic agents; carvedilol for treating hypertension, angina pectoris, and chronic heart failure; iohexol to enhance visibility of diagnostic X-ray imaging; silodosin for treating dysuria; laninamivir for anti-influenza treatment; edoxaban, an anticoagulant; teneligliptin and pioglitazone type 2 diabetes mellitus inhibitors; denosumab for treating bone complications; denosumab for treating osteoporosis; and prasugrel, an antiplatelet agent. Its generic pharmaceuticals also comprise colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus indication, as well as iron sucrose and ferric carboxymaltose injections for treating anemia. The company also provides over the counter products, such as Lulu, combination cold remedy; Daiichi Sankyo Ichoyaku, a multi-ingredient digestive remedy; Loxonin S, an antipyretic analgesic; Patecs, an antiphlogistic analgesic for external use; and Transino for treating melisma. In addition, it offers ActHIB, a haemophilus influenzae type b vaccine; Rotarix, a rotavirus vaccine; Influenza HA Vaccine; and Live Attenuated Measles/Rubella Combined Vaccine. Further, it manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates, as well as pharmaceuticals and drugs for animals. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

Founded in 1899

daiichi sankyo co ltd (D4S) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥123.0M
Compensation as of Fiscal Year 2015.

daiichi sankyo co ltd (D4S) Key Developments

Daiichi Sankyo Company, Limited Presents at The Redefining Early Stage Investments (RESI) Conference 2015, Sep-16-2015 03:00 PM

Daiichi Sankyo Company, Limited Presents at The Redefining Early Stage Investments (RESI) Conference 2015, Sep-16-2015 03:00 PM. Venue: Boston, Massachusetts, United States. Speakers: Weiyong Sun, Senior Director, External Scientific Affairs.

Daiichi Sankyo Company, Ltd. Signs Agreement with Translational Sciences, Inc. to Develop and Commercialize Thrombus Dissolving Agent, TS23

Daiichi Sankyo Company Ltd. announced that it has signed an exclusive licensing agreement with Translational Sciences, Inc. to develop and commercialize its novel thrombus (blood clot) dissolving agent, TS23, which is currently undergoing Phase I clinical trials. Based on this agreement, Daiichi Sankyo will pay Translational Sciences unspecified fees, milestones and royalties for exclusive rights to globally develop and commercialize TS23. This agreement with Translational Sciences, Inc. for Daiichi Sankyo to develop and commercialize this unique thrombus dissolving agent, TS23, is in line with the Daiichi Sankyo R&D strategy to expand its portfolio in the prevention and treatment of thrombosis.

Adimmune and Daiichi Sankyo Signs Agreement to Produce Influenza Vaccine

Adimmune has signed an agreement with Daiichi Sankyo on the manufacture and marketing of an influenza vaccine in Japan. Under the agreement, Adimmune will manufacture flu stock solution for four million doses per year in the first five-year stage, which Daiichi Sankyo will then use to produce the vaccine. Financial details were not disclosed. The co-operation is a positive development for Adimmune building on its recent approval to supply influenza stock solution to the European market as well as Taiwan's biotech industry, which is seeking fresh investment from overseas as it struggles to pull out of a slump and looking to the 2016 election for new, research and development (R&D)-friendly policies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
D4S:GR €15.36 EUR +0.187

D4S Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioCryst Pharmaceuticals Inc $12.44 USD +0.83
BioMerieux €94.73 EUR -1.08
Exelixis Inc $5.91 USD +0.18
Infinity Pharmaceuticals Inc $8.92 USD +0.64
Ipsen SA €55.94 EUR +1.15
View Industry Companies

Industry Analysis


Industry Average

Valuation D4S Industry Range
Price/Earnings 25.3x
Price/Sales 1.6x
Price/Book 1.2x
Price/Cash Flow 4.5x
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at